Disclosures for "VISIONARY-MS Top-line Results: A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo-controlled Study to Assess the Safety and Efficacy of CNM-Au8, a Catalytically Active Gold Nanocrystal Suspension in Relapsing Multiple Sclerosis ")
-
Michael Barnett has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sydney Neuroimaging Analysis Centre. An immediate family member of Michael Barnett has received stock or an ownership interest from RxMx. The institution of Michael Barnett has received research support from Genzyme Sanofi. The institution of Michael Barnett has received research support from Biogen. The institution of Michael Barnett has received research support from Novartis.
-
Dr. Beadnall has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Beadnall has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Beadnall has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. The institution of Dr. Beadnall has received research support from MSBase Foundation.
-
Alexander Klistorner has nothing to disclose.
-
Dr. Sergott has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Sergott has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. Dr. Sergott has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen.
-
Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Horizon. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi/Genzyme. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunovant. Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech/ROche. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Signant-2022. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for IQVIA. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Greenberg has received personal compensation in the range of $0-$499 for serving as a Consultant for Intervenn. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for TWI. Dr. Greenberg has stock in GenrAb. The institution of Dr. Greenberg has received research support from CLENE Nanomedicine. The institution of Dr. Greenberg has received research support from Anokion. The institution of Dr. Greenberg has received research support from Regeneron. Dr. Greenberg has received intellectual property interests from a discovery or technology relating to health care. Dr. Greenberg has received publishing royalties from a publication relating to health care. Dr. Greenberg has a non-compensated relationship as a Scientific Board with Siegel Rare Neuroimmune Association that is relevant to AAN interests or activities.
-
Mr. Rynders has received personal compensation for serving as an employee of Clene Nanomedicine. An immediate family member of Mr. Rynders has received personal compensation for serving as an employee of Recursion Pharmaceuticals. Mr. Rynders has stock in Clene Nanomedicine. An immediate family member of Mr. Rynders has stock in Recursion Pharmaceuticals.
-
Dr. Ho has received personal compensation for serving as an employee of Clene Nanomedicine. Dr. Ho has stock in Clene Nanomedicine.
-
Mr. Evan has received personal compensation for serving as an employee of Clene Nanomedicine. Mr. Evan has stock in Clene Nanomedicine .
-
Mr. Evan has received personal compensation for serving as an employee of Clene Nanomedicine. An immediate family member of Mr. Evan has received personal compensation for serving as an employee of Clene Nanomedicine. Mr. Evan has stock in Clene Nanomedicine Inc.
-
Mr. McBride has nothing to disclose.
-
Mr. Hartford has received personal compensation for serving as an employee of Clene Nanomedicine. Mr. Hartford has received personal compensation for serving as an employee of Takeda. Mr. Hartford has stock in AbbVie. Mr. Hartford has stock in Takeda.
-
Dr. Glanzman has received personal compensation for serving as an employee of Clene Nanomedicine Inc. Dr. Glanzman has stock in Clene Nanomedicine Inc .
-
Mr. Hotchkin has received personal compensation for serving as an employee of Clene Nanomedicine, Inc. Mr. Hotchkin has stock in Clene Nanomedicine, Inc.